Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes

Tarun Kumar Jeloka1*, Datta Jayanta2, Suresh Babu Vallamkonda1, Sujeet Narayan Charugulla1, Gupta Namita4

1Department of Nephrology and Kidney Transplant, Aditya Birla Memorial Hospital Pune, India
2Department of Nephrology and Renal Transplant Surgery, Columbia Asia Hospital, Kolkata, India
3Department of Nephrology, Yashoda Hospital, Hyderabad, India
4Department of Medical Affairs, Dr Reddy’s Laboratories, Hyderabad, India

*Corresponding author: Jeloka Tarun K, Email: tjeloka@yahoo.com

Implication for health policy/practice/research/medical education:
The main advantages of darbepoetin are efficacious anemia correction and reduction of blood transfusions.

Please cite this paper as: Jeloka TK, Jayanta D, Vallamkonda SB, Charugulla SN, Namita G. Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes. J Nephropharmacol. 2020;9(2):e14. DOI: 10.34172/npj.2020.14.

Introduction

In India, the prevalence of chronic kidney disease (CKD) varies from less than 1% to 13% with around 48% of patients presenting in Stage 5 (1,2). In 2016, the International Society of Nephrology Kidney Disease Data Center Study showed an estimated prevalence of 17% in Indian patients (2). Over 130 000 people are on dialysis in India and every year it is added up by about 232 per million (3). About 79%–97% of individuals with chronic renal failure stages 3-5 suffer from anemia, which increases the risk of cardiovascular disease (CVD) and all-cause mortality (1).

The current standard therapy for anemia in CKD patients (both pre-dialysis and dialysis) includes the use of oral or intravenous (IV) iron supplementation and erythropoiesis-stimulating agents (ESAs). In clinical studies, ESAs have been shown to increase the hemoglobin (Hb) levels (4). However, Kidney Disease Improving Global Outcomes (KDIGO) 2012 guideline recommends ESA therapy initiation if Hb concentration remains <10 g/dL despite repletion with oral or IV iron therapy (5). Depending on half-life, two types of ESAs have got regulatory approval for the treatment of CKD: short-acting [epoetin alfa, recombinant human erythropoietin (rHuEPO; approved by Food and Drug Administration (FDA) in June 1989)] and long-acting [darbepoetin alfa (approved by FDA on September 17, 2001), continuous erythropoietin receptor activator (CERA), approved by FDA on November 14, 2007)].

Darbepoetin alfa has simplified the management of anemia because of its equivalent dose requirement for both IV and subcutaneous (SC) administration and extended dosing intervals over rHuEPO (6). In addition, several studies have confirmed the efficacy of darbepoetin...
Darbepoetin alfa in CKD and dialysis patients (CKD5D) (7-10). Over the years, comparison of the efficacy of epoetin alfa and darbepoetin alfa has contradictory results (4,6). The current review focuses on the efficacy and safety outcomes with darbepoetin alfa directly compared with placebo or other ESAs while treating the anemia of CKD/CKD5D.

Materials and Methods

Search strategy

Article searches were carried out on PubMed and Google Scholar from 1999 to 2019. The keywords used were anemia, darbepoetin alfa, CKD, epoetin alfa, erythropoiesis-stimulating agent, renal replacement therapy and hemodialysis. Literature was not limited by study design and all types of studies including randomized, double-blind, cohort, case-control, observational and retrospective studies were included. Animal studies were not considered for the efficacy and safety review. All relevant literature has been included in this study; however, any literature not included is unbiased, unintentional and unconditional.

Darbepoetin alfa; a second-generation erythropoietin (EPO) analogue

Darbepoetin alfa is a hyper-glycosylated EPO analogue that has prolonged survival in the circulation (11). Darbepoetin alfa was approved by the FDA and the European Medicines Agency EMA in 2001 for the treatment of anemia in patients with CKD and cancer (11). The terminal half-life of IV darbepoetin-alfa was approximately three times longer than that of IV epoetin-alfa (25.3 versus 8.5 hours) (11).

Routes of administration

Darbepoetin alfa can be used by both intravenous (IV), and subcutaneous (SC) routes (12). Previous studies have demonstrated that dose requirements for darbepoetin alfa IV or SC are comparable and target hemoglobin or hematocrit levels can be achieved and maintained using either an IV or SC route with darbepoetin alfa (12). Aarup et al conducted a crossover study to compare IV versus SC dose requirements of darbepoetin alfa in 71 stable hemodialysis patients. IV darbepoetin alfa was associated with 95% probability of a mean dose reduction between 1.2% and 28% (P = 0.036) (13). Absorption with SC route is more rapid in children (14).

Dose and frequency

The labeling for darbepoetin alfa recommends that it be given either IV or SC at the dose of 0.45 μg/kg per week or 0.75 μg/kg once every two weeks for patients with CKD on dialysis. The approved dosage for patients with CKD not on dialysis is 0.45 μg/kg at four-week intervals (15). Darbepoetin alpha at lower dose frequency (0.45 μg/kg, once weekly), showed similar mean change in Hb levels as EPO in Indian pre-dialysis in individuals with chronic renal failure with anemia (11.28 g/dL versus 11.02 g/dL; 95% CI -0.62, 1.09; P = 0.5837) (16). Another randomized phase-III trial from India, comparing the efficacy and safety of darbepoetin alfa and EPO in patients with end-stage renal disease (ESRD), has also demonstrated similar results with the difference in mean Hb change between these two groups being insignificant − 0.01 g/dL (95% CI − 0.68 to −0.66, P = 0.97) (17).

In 2009, a meta-analysis investigated the relative dose savings in patients receiving dialysis when switched from epoetin alfa or beta to darbepoetin alfa. Using the conversion ratio of 200:1, it reported an average 30% dose savings (18). In 2018, Woodland et al reported a dose conversion ratio, from EPO to darbepoetin alpha, of greater than 350:1 by 3-month in hemodialysis (HD) patients (19).

Achieved Hb target

About 95% to 97% of CKD patients (ESA naive) had achieved Hb levels between 11 and 13 g/dL, after almost 5 weeks of starting de novo Q2W administration of SC darbepoetin alfa (10,20). Administration of darbepoetin alfa either at Q2W or QM could maintain the Hb levels ≥10 g/dL in most of the patients with CKD (77.78%), not on dialysis (21). In the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study, over 4,000 diabetics with CKD stages 3 and 4 were randomly assigned to darbepoetin alfa (n=2012) to achieve a target Hb level of 13g/dL and to placebo (n=2026) with rescue darbepoetin alfa when the Hb level was <9 g/dL. At three months of post-treatment, the darbepoetin alfa group significantly achieved the median Hb level of 12.5 g/dL, as compared with 10.6 g/dL in the placebo group (22). A review (33 studies, n=5526) found longer-acting ESAs (darbepoetin and CERA) to be non-inferior to rhuEPO in achieving the Hb target (23).

Maintenance of Hb levels with darbepoetin alfa

In 2009, Krause and colleagues compared the efficacy and safety profile of de novo every-other-week darbepoetin alfa in ESA-naive subjects aged <65, 65–74 and ≥75 years of age with CKD (not receiving dialysis). The analysis suggested that darbepoetin alfa can achieve and maintain Hb levels in patients with CKD with de novo every-other-week administration (24).

All-cause mortality

In 2017, a systematic review (27 studies involving 5410 adults with CKD) compared the risk of mortality between patients randomly assigned to CERA, darbepoetin and EPO and reported no significant difference between the treatment (RR 1.07, 95% CI 0.73 to 1.57; RR 1.11, 95% CI 0.75 to 1.65) (25). Similar results have been reported from another systematic review of 9 trials involving 2024 individuals with chronic renal failure (odds ratio [OR] 1.33; 95% CI: 0.88–2.01) (26). A Quasi-experimental
Cardiovascular events
Randomized controlled trials (RCTs) on pre-dialysis patients with renal anemia conducted in Japan, found no difference between the darbepoetin group (target Hb, 11.0–13.0 g/dL) and the rHuEPO group (target Hb, 9.0–11.0 g/dL) in terms of safety, including risk for CV events. However, a significant decrease in the left ventricular mass index was seen in the darbepoetin group (28). The Darbepoetin Alfa for Renal Anemia Management in Japan (DREAM-J) surveillance study has also found no increase in the incidence of CV-related adverse events (AEs) with higher Hb levels (29).

Cerebrovascular thrombosis and stroke
The results of TREAT study confirmed an increased incidence of cerebral infarction among CKD patients in the higher hematocrit arm, while the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study pointed to an increase in stroke rates among CKD patients with the higher target for Hb concentration (22,30). However, systematic reviews of ESA therapy have demonstrated that higher target Hb (13–15 g/dL) could lead to increased risk of stroke, worsening hypertension, and vascular access thrombosis (31,32). A study by Akizawa et al reported stroke only in one patient from the high Hb group receiving darbepoetin and in three patients from the low Hb group receiving rHuEPO (28). Another study by Vanrenterghem et al also showed no significant difference (P ≥ 0.682) in incidence rate of vascular access thrombosis between treatment groups (darbepoetin alfa 10%, rHuEPO 9%) (8).

Additional blood transfusions and iron therapy
ESAs have shown to reduce the need for RBC transfusions and iron therapy in CKD patients with anemia (33-35). A systematic review (32 studies, n=9414) by Palmer et al pointed to an increase in stroke rates among CKD patients with the higher target for Hb concentration (22,30). However, systematic reviews of ESA therapy have demonstrated that higher target Hb (13–15 g/dL) could lead to increased risk of stroke, worsening hypertension, and vascular access thrombosis (31,32). A study by Akizawa et al reported stroke only in one patient from the high Hb group receiving darbepoetin and in three patients from the low Hb group receiving rHuEPO (28). Another study by Vanrenterghem et al also showed no significant difference (P ≥ 0.682) in incidence rate of vascular access thrombosis between treatment groups (darbepoetin alfa 10%, rHuEPO 9%) (8).

Quality of life outcomes with darbepoetin alfa
A randomized single-blind study reported statistically significant improvements in some SF-36 and FACT-An subscale score, with darbepoetin alfa. However, mean SF-36 score was comparable between the darbepoetin alfa (51.4 [95 % CI 48.0, 54.9]) and placebo (46.7 [40.9, 52.5]) groups (37). In addition, it has shown improvement in FACT-Fatigue and EQ-5D scores (37). Various studies have also shown moderate-to-large improvements in fatigue with ESA treatment for anemia (38). Interestingly, the striking improvements in fatigue symptom among patients treated to achieve Hb level lower than a target of 10–12 g/dL show the significance of partial anemia correction with ESA therapy (38). One meta-analysis by Palmer et al found limited and inconclusive evidence for effects of ESAs on health-related quality of life (HRQoL) due to the selective reporting by the RCTs (32). This finding was further supported by Collister et al wherein significant heterogeneity amongst studies ruled out meaningful positive effects of ESAs on HRQoL in patients with CKD (39). However, another systematic literature review by Gandra et al reported that the treatment of anemia with ESA therapy improved energy and physical function in CKD patients, not on dialysis (40).

Safety outcomes with darbepoetin alfa
The tolerability and safety profile for darbepoetin alfa is as good as rHuEPO. A prospective, phase IV, observational registry reported 434 AEs in 162 children with CKD who received darbeopoetin alpha; peritonitis (10.0 %) was most common AEs followed by gastroenteritis (6.0 %), and hypertension (4.1 %). In this study, only 48 children received ≥1 transfusion (41). A multicenter prospective study by Hattori et al reported 24 AEs in 44% of patients receiving darbepoetin for CKD associated anemia; however, no definite relation was observed between darbepoetin alfa and AEs (42). Another Japanese study, evaluating the safety and efficacy of darbepoetin alfa in children (n=31) with CKD on peritoneal dialysis (PD)/HD or pre-dialysis, reported total 87 AEs in 87.1 % children; none of which were related to the study drug (43). The results regarded darbepoetin as an effective and safe alternative to rHuEPO in children with CKD.

In 2019, a study comparing the safety of two darbepoetin alfa formulations in healthy male volunteers reported negative anti-drug antibody reactivity for all samples collected for up to 360 or 264 hours after SC or IV administration from both intervention groups (44). Few cases of pure red cell aplasia (PRCA) have been reported in CKD patients receiving treatment with darbepoetin, predominantly by SC route (45). However, Prospective Immunogenicity Surveillance Registry (PRIMS) found low PRCA risk after SC administration of a new coated-stopper syringe presentation of different ESAs (46).

Economic outcomes
In Greece, an analysis conducted from public third-party payer perspective, demonstrated the lowest overall costs per patient with darbepoetin alfa compared to other ESAs.

http://www.jnephropharmacology.com
at €8210 and €6689, for patients on HD or PD, respectively (47). In 2017, a randomized controlled trial by Woodland et al. reported reduction in cost of $1876 per patient per year for darbepoetin alpha than EPO ($P = 0.02) in HD patients (19).

**Risk with darbepoetin**

In 2007, the USFDA mandated a black box warning for all ESAs following reports of increased AEs with higher doses of ESAs. The deciding factor for this black box warning was the data obtained from the Normal Hematocrit Cardiac Trial (NHCT), the CHOIR study, and the CV Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) study (30,48,49). An increased risk of vascular access thrombosis and heart attacks were reported by NHCT for dialysis patients in the higher hematocrit arm, while an increase in CV events and mortality rates among pre-dialysis patients with a higher target for Hb concentration were reported by the CHOIR study (30,48). These findings were further supported by few trials demonstrating that the correction of anemia in CKD patients with ESAs does not confer a beneficial effect on mortality, CV, or renal outcomes (22,29,50). The CREATE study showed a higher risk of ESRD requiring dialysis among the patients targeted to higher hematocrit levels (49).

**Recommendations for improving administration of ESAs**

In response to the three trials raising concerns on safety of ESAs in CKD patients with anemia, changes in position statements and management guidelines were published (Table 1) (5). KDIGO guideline recommends ESA therapy initiation in patients whose hemoglobin concentration has fallen below 10 g/dL even after addressing all the reversible causes (5). In certain patients considered suitable for transplantation or who are likely to avoid blood transfusion, ESAs can be initiated to correct anemia in chronic renal failure patients (15). The US Food and Drug Administration (USFDA) has even obviated the need to mention target Hb on the label and recommends that ESA should be used in lowest possible dose to reduce red blood cell transfusion (51). Thus, ESA therapy should be initiated in CKD patients displaying moderate anemia who are moderately symptomatic. Various recommendations from different guidelines for ESA administration in patients with CKD have changed over the years owing to safety issues. These changes in guidelines are listed in Table 1 (5,15,51-55).

**Conclusion**

Over the past 10 years, clinical treatment strategies for anemia in CKD patients have changed markedly, which included ESA administration, IV iron supplementation, and red blood cell transfusions. The clinical approval of darbepoetin has brought about transformation in the treatment of anemia in CKD patients. The main advantages of darbepoetin are efficacious anemia correction and reduction of blood transfusions, as well as improvements in HRQoL. More population-specific studies are required as currently published studies are insufficient to delineate Hb limit and risk-benefit ratio for darbepoetin.

**Authors’ contribution**

TJ and SJC searched the data and prepared the draft of the manuscript. JD and SVB edited and finalized the paper. All authors read and signed the final manuscript.

**Conflicts of interest**

Authors declare no conflict of interests.

---

**Table 1.** Change in guidelines recommendations for ESA administration in CKD patients

| Guideline       | Year | Recommendations for ESA use                                                                 |
|-----------------|------|---------------------------------------------------------------------------------------------|
| NKF-DOQI        | 1997 | • Hb target range from 11 to 12 g/dL                                                        |
| FDA             | 2007 | • Issued a black box warning to maintain the Hb levels within the range of 10-12 g/dL and not to exceed 12 g/dL in ESA-treated patients |
| ERBP            | 2010 | • ESA therapy may be initiated in CKD ND patients with Hb concentration <10 g/dL             |
|                 |      | • In CKD 5D patients, it should be used to avoid Hb fall below 9 g/dL when the Hb is between 9.0–10.0 g/dL |
| FDA             | 2011 | • Remove the concept of a “target hemoglobin range”                                         |
|                 |      | • Use lowest ESA dose to reduce the need for red blood cell transfusions                     |
| KDIGO           | 2012 | • ESA therapy should not be initiated when the hemoglobin level is ≥10 g/dL                  |
|                 |      | • Individualization of the ESA therapy should be considered in patients who are likely to benefit in terms of quality of life |
| NICE            | 2015 | • ESA therapy should be considered in patients who are more likely to benefit in terms of both physical functioning and quality of life |
|                 |      | • Hb target range from 10 to 12 g/dL                                                        |
| Renal association | 2017 | • ESA therapy should be considered in patients who are more likely to avoid blood transfusion and to have benefit in terms of both physical functioning and quality of life |
|                 |      | • Hb target range from 10 to 12 g/dL                                                        |

Abbreviations: CKD, Chronic kidney disease; CKD ND, non-dialysis chronic kidney disease; CKD 5D, indicate end-stage renal disease patients who undergo chronic dialysis; ESA, Erythropoiesis-stimulating agents; Hb, Hemoglobin.
Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
None.

References
1. Apsangikar P, Chaudhry S, Naik M, Deoghare S, Joseph J. Comparative efficacy and safety of biosimilar darbepoetin alfa in adults with anaemia of chronic kidney disease. Indian J Transplant. 2018;12:30-34. doi: 10.4103/iijt.iijt_62_17.
2. Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (JSN-KDDC): a cross-sectional study. The Lancet Global health. 2016;4:e307-19. doi: 10.1016/s2214-109x(16)00071-1.
3. Varughese S, Abraham G. Chronic kidney disease in India: a clarion call for change. Clin J Am Soc Nephrol. 2018;13:802-4. doi: 10.2215/cjn.09180817.
4. Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, et al. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anaemia: a systematic review. Clinical therapeutics. 2014;36:594-610. doi: 10.1016/j.clinthera.2014.02.007.
5. Druke TB, Parfrey PS. Summary of the KDIGO guideline on anaemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82:952-60. doi: 10.1038/ki.2012.270.
6. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus. 2009;2:9-17. doi: 10.1093/ndtplus/fsn175.
7. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatty R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anaemia in hemodialysis patients. Am J Kidney Dis. 2002:40:110-8. doi: 10.1053/ajkd.2002.33919.
8. Vanreterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NE, et al. Randomized trial of darbepoetin alfa for treatment of renal anaemia at a reduced dose frequency compared with HuEPO in dialysis patients. Kidney Int. 2002;62:2167-75. doi: 10.1046/j.1523-1755.2002.00657.x.
9. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant. 2003;18:362-9.
10. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R. Treatment of anaemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol. 2003;23:106-11. doi: 10.1159/000068041.
11. Fernandez H, Singh AK. Chapter 51 - Management of Anemia in Chronic Kidney Disease. In: Kimmel PL, Rosenberg ME, eds. Chronic Renal Disease. San Diego: Academic Press; 2015. p. 624-633.
12. Brunnkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant. 2004;19:1224-30.
13. Aarup M, Bryndum J, Dieperink H, Joffe P. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant. 2006;21:1312-6. doi: 10.1093/ndt/gkl048.
14. Deicher R, Horl WH. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64:499-509. doi: 10.2165/00003495-200464050-00004.
15. Mikhael A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18:345.doi: 10.1186/s12882-017-0688-1.
16. Mehta KS, Sinha SD, Vamsi B, Reddy B, Naidu NR, Thakur PA, et al. Darbepoetin alfa versus erythropoietin alfa for treatment of renal anaemia in patients with chronic kidney disease at the pre-dialysis stage: a randomized non-inferiority trial. J Assoc Physicians India. 2019;67:62-66.
17. Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, et al. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anaemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrol. 2019;20:90. doi: 10.1186/s12882-019-1209-1.
18. Bonafont X, Bock A, Carter D, Brunnhorst R, Carrera F, Iskedjian M, et al. A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. NDT Plus. 2009;2:347-53. doi: 10.1093/ndtplus/sfp097.
19. Woodland AL, Murphy SW, Curtis BM, Barrett BJ. Costs associated with intravenous darbepoetin versus epoetin therapy in hemodialysis patients: a randomized controlled trial. Can J Kidney Health Dis. 2017;4:2054358117716461. doi: 10.1177/2054358117716461.
20. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, et al. Darbepoetin alfa effectively treats anaemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol. 2004;24:453-60. doi: 10.1159/000080452.
21. Al Raisi F, Al Salmi I, Kamble P, Al Shehri M, Shaheen FA. Initiation of darbepoetin for management of anaemia in non-dialysis-dependent patients with chronic kidney disease. Saudi J Kidney Dis Transpl. 2016;27:1182-1187.
22. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32. doi: 10.1056/NEJMoa0907845.
23. Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev. 2014;Cd003895. doi: 10.1002/14651858.CD003895.pub3.
24. Krause MW, Raja R, Agarwal A, Silver MR, Scarlata D, Scharra A, et al. Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Drugs Aging. 2009;26:665-75. doi: 10.2165/11316450-000000000-00000.
25. Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2017;8:CD009904. doi: 10.1002/14651858.CD009904.pub2.

26. Wilhelm-Leen ER, Winkelmayr WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2015;66:69-74. doi: 10.1053/j.ajkd.2014.12.012.

27. Winkelmayr WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding Y, Chertow GM, et al. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015;66:106-13.

28. Akizawa T, Gejyo F, Nishi S, Iino Y, Watanabe Y, Suzuki M, et al. Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study. Ther Apher Dial. 2011;15:431-40. doi: 10.1111/j.1747-9987.2011.00931.x.

29. Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, et al. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol. 2019;23:231-43. doi: 10.1007/s10157-018-1632-9.

30. Singh AK, Szczez L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98. doi: 10.1056/NEJMoa062276.

31. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in anemia of chronic kidney disease. Cochrane Database Syst Rev. 2017;8:Cd00259. doi: 10.1002/14651858.CD00259.pub5.

32. Kessler M, Martinez-Castelaó A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. for red cell aplasia: past, present, and future considerations. Nephron Clin Pract. 2012;121:95-101. doi: 10.1159/000345158.

33. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link K, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201-16. doi: 10.1016/j.ejca.2004.07.015.

34. Covic A, Nistor I, Donciu MD, Dumea R, Bolignano D, Goldsmith D. Erythropoiesis-stimulating agents (ESA) for preventing the progression of chronic kidney disease: a meta-analysis of 19 studies. Am J Nephrol. 2014;40:263-79. doi: 10.1159/000366025.

35. Koulouridis I, Afayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metagression analysis. Am J Kidney Dis. 2013;61:44-56. doi: 10.1053/j.ajkd.2012.07.014.

36. Kessler M, Martinez-Castelaó A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. for red cell aplasia: past, present, and future considerations. Nephron Clin Pract. 2012;121:95-101. doi: 10.1159/000345158.

37. Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, et al. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011;6:845-55.

38. Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012;27:2418-25. doi: 10.1093/ndt/gfr697.

39. Collister D, Komenda P, Hiebert B, Gunasekara R, Xu Y, Eng F, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2016;164:472-8. doi: 10.7326/m15-1839.

40. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis. 2010;55:519-34. doi: 10.1053/j.ajkd.2009.09.019.

41. Schaefer F, Hoppe B, Jungraithmayr T, Klaus G, Pape L, Farouk M, et al. Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study. Pediatr Nephrol. 2016;31:443-53.

42. Hattori M, Matsunaga A, Akioka Y, Fujinaga S, Nagai T, Uemura O, et al. Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: a multicenter prospective study in Japan. Clin Exp Nephrol. 2013;17:582-8. doi: 10.1007/s10157-012-0714-3.

43. Hattori M, Uemura O, Hataya H, Ito S, Hisano M, Ohta T, et al. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan. Clin Exp Nephrol. 2014;18:634-41. doi: 10.1007/s10157-013-0859-8.

44. Kim S, Hong T, Ko JW, Huh W and Kim JR. Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers. BioDrugs. 2019;33:101-112. doi: 10.1007/s40259-018-0323-0.

45. McCoy JM, Stonecash RE, Courneyer D, Rossert J, Nissenson AR, Raisch DW, et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48:1754-62. doi: 10.1111/j.1537-2995.2008.01749.x.

46. Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30:451-60. doi: 10.1093/ndt/gfu297.

47. Kourlaba G, Boletis I, Goumenos D, Iatrou C, Papagiannopoulos V, Tsiraki G, et al. Cost consequence analysis of darboepokin alfa for the treatment of anemia Due To Chronic Kidney Disease (Ckd) In Greece. Value Health. 2014;17:468-9. doi: 10.1016/j.jval.2014.08.1323.

48. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normo of compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90. doi: 10.1056/NEJM199808273390903.

49. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84. doi: 10.1056/NEJMoa062276.
50. van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, et al. Hyporesponsiveness to Darbepoetin Alfa in patients with heart failure and anemia in the RED-HF study (reduction of events by darbepoetin alfa in heart failure): clinical and prognostic associations. Circ Heart Fail. 2018;11:e004431. doi: 10.1161/circheartfailure.117.004431.

51. Manns BJ and Tonelli M. The new FDA labeling for ESA-implications for patients and providers. Clin J Am Soc Nephrol. 2012;7:348-53.

52. Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346-59.

53. Padhi S, Glen J, Pordes BA and Thomas ME. Management of anaemia in chronic kidney disease: summary of updated NICE guidance. BMJ. 2015;350:2258.

54. Nordstrom BL, Luo W, Fraeman K, Whyte JL and Nordyke RJ. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. J Manag Care Pharm. 2008;14:858-69.

55. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30:192-240.